The secret ally: immunostimulation by anticancer drugs
It has recently become clear that the tumour microenvironment, and in particular the immune
system, has a crucial role in modulating tumour progression and response to therapy …
system, has a crucial role in modulating tumour progression and response to therapy …
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
The quest for treatment-free remission (TFR) and deep molecular response (DMR) in
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …
Reversible ON-and OFF-switch chimeric antigen receptors controlled by lenalidomide
Cell-based therapies are emerging as effective agents against cancer and other diseases.
As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen …
As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen …
Pharmacologic control of CAR-T cell function using dasatinib
Chimeric antigen receptor (CAR) T-cell therapy mediates high response rates in
relapsed/refractory B-cell malignancies. 1, 2, 3, 4 However, some patients experience …
relapsed/refractory B-cell malignancies. 1, 2, 3, 4 However, some patients experience …
Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma
JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington… - Clinical Cancer …, 2012 - AACR
Purpose: In this study, we assessed the specific role of BRAF (V600E) signaling in
modulating the expression of immune regulatory genes in melanoma, in addition to …
modulating the expression of immune regulatory genes in melanoma, in addition to …
COVID-19 in persons with chronic myeloid leukaemia
We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei
Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N= 4) or …
Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N= 4) or …
[HTML][HTML] Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing
M Qayed, JP McGuirk, GD Myers, V Parameswaran… - Cytotherapy, 2022 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is an individualized immunotherapy that
genetically reprograms a patient's T cells to target and eliminate cancer cells …
genetically reprograms a patient's T cells to target and eliminate cancer cells …
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S Mustjoki, M Ekblom, TP Arstila, I Dybedal… - Leukemia, 2009 - nature.com
Dasatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), predominantly targets BCR-ABL
and SRC oncoproteins and also inhibits off-target kinases, which may result in unexpected …
and SRC oncoproteins and also inhibits off-target kinases, which may result in unexpected …
Tricks with tetramers: how to get the most from multimeric peptide–MHC
L Wooldridge, A Lissina, DK Cole… - …, 2009 - Wiley Online Library
The development of fluorochrome‐conjugated peptide–major histocompatibility complex
(pMHC) multimers in conjunction with continuing advances in flow cytometry has …
(pMHC) multimers in conjunction with continuing advances in flow cytometry has …
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
A Kreutzman, V Juvonen, V Kairisto… - Blood, The Journal …, 2010 - ashpublications.org
In a proportion of patients with chronic myeloid leukemia (CML) being treated with dasatinib,
we recently observed large granular lymphocyte (LGL) expansions carrying clonal T-cell …
we recently observed large granular lymphocyte (LGL) expansions carrying clonal T-cell …